La chaîne d'options affiche les données clés des options sur actions de Verve Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Verve Therapeutics..

Verve Therapeutics (NASDAQ:VERV) Stock, Chaîne d'Options

VERVE THERAPEUTICS INC

Verve Therapeutics

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Verve Therapeutics Inc

MGI MEDIA & GAMES INVEST by MGI MEDIA & GAMES INVEST SE

Verve Group SE

Cryptocurrency company Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) reported first-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Thursday.</a>
Here are the highlights.
What Happened: Coinbase reported first-quarter total revenue of $2.03 billion. It missed a Street consensus estimate of $2.12 billion, according to data from Benzinga Pro.
Total revenue was up from $1.64 billion in last year's first quarter and down 10% from $2.27 billion in the fourth quarter.
Transaction revenue was $1.26 billion in the first quarter, up from $1.08 billion in last year's first quarter and down 19% quarter-over-quarter.
Subscription and services revenue was $698.1 million, which was in the company's previous guidance range of $685 million to $765 million. This revenue segment was up 9% quarter-over-quarter.
Adjusted earnings per share of $1.94 missed a Street consensus estimate of $2.11 for the quarter.
"This quarter, we made meaningful progress against our 2025 priorities of driving revenue, driving utility, and building the foundations to power the next decade of growth," the company said.
Coinbase said it gained market share in global spot and derivatives in the quarter.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) made up 27% of trading volume and 26% of transaction revenue, nearly identical to 27% for both metrics in the fourth quarter. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) was 11% of trading volume and 10% of transaction volume, compared to 10% for both in the fourth quarter.
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) represented 10% of transaction revenue in the first quarter and was less than 10% in the prior month.
XRP Token (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) represented 11% of trading volume and 18% of transaction revenue. In the fourth quarter, the crypto was 14% of transaction revenue and under 10% of trading volume.
Read Also: <a href="https://www.benzinga.com/25/05/45265214/coinbase-q1-earnings-preview-trump-inauguration-bitcoin-surge-and-more-items-to-watch">Coinbase Q1 Earnings Preview: Trump Inauguration, Bitcoin Surge And More Items To Watch</a>
What's Next: Coinbase highlighted sector progress, citing President Donald Trump&#8216;s executive order to establish a Strategic Bitcoin Reserve.
The company also said the dismissal of the SEC lawsuit against Coinbase was a "major judicial win."
"With growing regulatory clarity, we're accelerating our vision towards economic freedom," the company said.
Coinbase also highlighted its previous announced acquisition of Sentilia B.V (Deribit), a leading crypto options exchange. The acquisition is expected to close by the end of the year.
Guidance from Coinbase calls for second-quarter subscription and services revenue in a range of $600 million to $680 million.
April transaction revenue for the company was $240 million.
COIN Price Action: Coinbase stock is down 2.4% to $201.51 in after-hours trading Thursday. Its 52-week trading range is $142.58 to $349.75.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43713994/coinbase-q4-earnings-highlights-revenue-beat-consumer-trading-volume-940-billion-company-welcomes-dawn-of-a-new-era-for-crypto">Coinbase Acquires Deribit In $2.9B Deal To Expand Crypto Derivatives Business</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

News

Movers

Trading Ideas

$BTC

$ETH

$SOL

$XRP

COIN

Coinbase Slips On Q1 Miss, Highlights SEC 'Win' And Deribit Deal

WIIM

BLND

Blend Labs shares are trading higher. The company reported Q1 financial results.

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.13 by 76.92 percent. This is a 155.56 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $364.49 million which beat the analyst consensus estimate of $352.06 million by 3.53 percent. This is a 12.66 percent decrease over sales of $417.31 million the same period last year.

Earnings Beats

Nu Skin Enterprises Q1 Adj. EPS $0.23 Beats $0.13 Estimate, Sales $364.49M Beat $352.06M Estimate

INVESTOR PRESENTATION Q2 2025 Based on current information, we anticipate net revenue for the second quarter of 2025 to be within the range of $70 to $73 million and Adjusted EBITDA margin in the 3% to 4% range, excluding non-routine items. The quarterly sequential trends in net revenue and Adjusted EBITDA margin are driven largely by the timing of Easter, delays of some large events into the second half of the year, and typical quarter-to-quarter mix-shift in average ticket prices.

Guidance

Eventbrite Sees Q2 Sales $70.000M-$73.000M vs $74.92M Est

ZipRecruiter shares are trading lower.  The company reported Q1 financial results

FOXF

Fox Factory Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.60) by 26.88 percent. This is a 29.52 percent increase over losses of $(1.66) per share from the same period last year. The company reported quarterly sales of $9.42 million which beat the analyst consensus estimate of $7.63 million by 23.48 percent. This is a 62.82 percent increase over sales of $5.79 million the same period last year.

ASMB

Assembly Biosciences Q1 EPS $(1.17) Beats $(1.60) Estimate, Sales $9.42M Beat $7.63M Estimate

Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) sees Q2 sales of $36.000 million-$41.000 million vs $42.42 million analyst estimate.

BIRD

Allbirds Sees Q2 Sales $36.000M-$41.000M vs $42.42M Est

Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) affirms FY2025 sales outlook from $175.00 million-$195.00 million to $175.00 million-$195.00 million vs $184.86 million estimate.

Allbirds Affirms FY2025 Sales Guidance of $175.00M-$195.00M vs $184.86M Est

MITK

Mitek Systems shares are trading higher after the company reported better-than-expected Q2 financial results.

Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.61 by 77.05 percent. This is a 68.18 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $226.77 million which missed the analyst consensus estimate of $254.54 million by 10.91 percent. This is a 5.18 percent decrease over sales of $239.16 million the same period last year.

Earnings Misses

Mach Natural Resources Q1 EPS $0.14 Misses $0.61 Estimate, Sales $226.77M Miss $254.54M Estimate

Entravision Comms (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>) reported quarterly losses of $(0.53) per share. This is a 562.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $91.85 million in sales this quarter. This is a 17.49 percent increase over sales of $78.18 million the same period last year.

Entravision Comms Q1 EPS $(0.53) Down From $(0.08) YoY, Sales $91.85M Up From $78.18M YoY

INOD

Innodata FY2025 Revenue expected to be $238.65M+ vs $242.26M Est

Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) reported quarterly losses of $(0.37) per share. This is a 37.29 percent increase over losses of $(0.59) per share from the same period last year. The company reported $785.82 thousand in sales this quarter. This is a 84.48 percent increase over sales of $425.95 thousand the same period last year.

LODE

Comstock Q1 EPS $(0.37) Up From $(0.59) YoY, Sales $785.82K Up From $425.95K YoY

Rackspace Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

LYFT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) released its first-quarter results after Thursday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/05/b45298979/lyft-reports-strong-q1-2025-financial-results">of the report. </a>
The Details: Lyft reported quarterly earnings of one cent per share, which beat the analyst consensus estimate of losses of one cent. Quarterly revenue came in at $1.45 billion, which missed the Street estimate of $1.47 billion.
Lyft&#8217;s board of directors authorized an increase to its share repurchase program to a new total of $750 million. The company said it intends to utilize $500 million of this authorization within the next 12 months, $200 million of which will be used within the next three months.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45292652/thursdays-top-5-trending-stocks-whats-going-on-with-d-wave-novavax-carvana?utm_source=articleShare">Thursday&#8217;s Top 5 Trending Stocks: What&#8217;s Going On With D-Wave, Novavax, Carvana?</a>
For the first quarter, Lyft reported: 
<ul>
<li>Gross Bookings of $4.2 billion, up 13% year over year.</li>
<li>Rides grew 16% year over year to 218.4 million, a record first quarter.</li>
<li>Active Riders growth accelerated to 11% year over year to 24.2 million, a record first quarter.</li>
</ul>
&#8220;Q1 marked Lyft&#8217;s 16th consecutive quarter of double-digit year-over-year Gross Bookings growth demonstrating the resilience and momentum of our customer-obsessed strategy,&#8221; said Lyft CEO David Risher.
&#8220;In the last week of March, rides reached the highest weekly levels in our history and dual-app drivers reported a 23 percentage point preference for Lyft. With our expansion into new demographics via Lyft Silver and into Europe with our planned FREENOW acquisition, we&#8217;re putting all the pieces in place for sustained, market-leading performance,&#8221; Risher added. 
LYFT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Lyft stock was up 7.30% at $13.95 after-hours Thursday.  
Read Next:&nbsp;
• <a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says </a>
Photo: Shutterstock

Buybacks

After-Hours Center

LYFT

Lyft Shares Drive Higher After Mixed Q1 Report, Stock Buyback Program Raised To $750 Million

Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) reported quarterly losses of $(2.73) per share which missed the analyst consensus estimate of $(2.21) by 23.53 percent. This is a 22.44 percent increase over losses of $(3.52) per share from the same period last year. The company reported quarterly sales of $32.11 million which missed the analyst consensus estimate of $44.02 million by 27.05 percent. This is a 18.34 percent decrease over sales of $39.33 million the same period last year.

Allbirds Q1 GAAP EPS $(2.73) Misses $(2.21) Estimate, Sales $32.11M Miss $44.02M Estimate

Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 6.52 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $2.35 million which beat the analyst consensus estimate of $1.75 million by 34.46 percent. This is a 3.13 percent decrease over sales of $2.43 million the same period last year.

CRBU

Caribou Biosciences Q1 EPS $(0.43) Beats $(0.44) Estimate, Sales $2.35M Beat $1.75M Estimate

The Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which follows the Nasdaq 100 Index, jumped 1.2% Thursday as a combination of political and economic events lifted investor mood and stoked interest in megacap tech stocks again. The Nasdaq 100 rose by almost 2%, supporting QQQ in beating <a href="https://www.benzinga.com/etfs">broad-market peers</a> on a day characterized by increased demand for risk assets.
QQQ Vs. ONEQ
The Invesco QQQ ETF continues to be a popular vehicle for those looking for concentrated exposure to the largest growth and non-financial technology stocks in the U.S., such as heavyweights Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). Famous for its tech-heavy bias and high liquidity, QQQ tends to rise with market enthusiasm around innovation, deregulation and macroeconomic catalysts.
A similar fund, the Fidelity Nasdaq Composite Index ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEQ#NASDAQ">ONEQ</a>), provides more coverage by tracking the entire Nasdaq Composite Index, including more than 3,000 stocks of a wider group of sectors and market caps. While QQQ tends to be more volatile because of its concentration on megacap tech, ONEQ, which also rose more than 1% on Thursday, provides more diversified exposure, possibly ironing out performance through sector-specific dips. Both ETFs gauge investor attitudes toward growth and technology, but QQQ is still the more aggressive bet for investors betting large on the tech industry&#8217;s upside.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45299690/oil-etfs-heat-up-as-opec-pump-up-us-uk-trade-deal-china-talks-fuel-rally">Oil ETFs Heat Up As OPEC+ Pump-Up, US-UK Trade Deal, China Talks Fuel Rally</a>
What Drove QQQ Today?
A focal point in Thursday&#8217;s upsurge was the declaration of the <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">U.S.-U.K. trade agreement</a>, which, while symbolic in parts, signaled markets that geopolitical relationships could be stabilizing. The agreement includes lowering tariffs on vehicles produced in the UK and British counter purchases of U.S. products, including Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) planes. Although important tariff levels, in particular a 10% across-the-board levy, are untouched, investors saw the news as a move in the direction of wider global coordination.
Moreover, the impending talks with China scheduled for May 10 are also keeping hopes up.
Meanwhile, markets cheered initially on news the Trump administration would roll back <a href="https://www.benzinga.com/news/global/25/05/45269811/chip-stocks-rise-as-trump-reportedly-plans-to-roll-back-biden-era-ai-export-curbs">Biden-era restrictions on AI chip exports</a>. The likelihood of a rollback sent semiconductor shares, such as Nvidia, AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), showing afternoon gains of over 1%. Because the Nasdaq-100 index is heavily invested in the semiconductor space, QQQ directly took advantage of the rally. The hope of reduced AI chip sales restrictions eased concerns over a deceleration in global semiconductor demand, one of the index&#8217;s major growth pillars.
Federal Reserve Chairman Jerome Powell moderated some of the euphoria with a warning note, cautioning that an imbalanced tariff policy could increase inflationary pressures and drag on economic growth. Nevertheless, risk-on sentiment dominated after Trump&#8217;s declaration that the U.S. economy is ready for &#8220;the biggest tax cuts in history&#8221; and his firm urging investors to &#8220;go out and buy stock.&#8221;
Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), another QQQ heavyweight, gained 2% after the company addressed fears of waning search queries on Apple platforms—a clarification that regained some lost ground in the previous session&#8217;s 7% decline.
These advances combined renewed faith in U.S. technology stocks and validated the QQQ ETF&#8217;s role as a barometer of optimism in the market for innovation, deregulation, and growth-oriented policy realignments. Amidst investors scrutinizing headlines that spanned from geopolitics to generative AI, QQQ became an investors&#8217; go-to vehicle for beta exposure in a tech-fueled bounce-back — cementing its place not only as a passive index fund tracker but also as a sentiment litmus test for the direction of U.S. innovation.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45293109/are-your-health-care-etfs-safe-trumps-new-policies-may-trigger-shockwaves-across-pharma-stock">Are Your Health Care ETFs Safe? Trump&#8217;s New Policies May Trigger Shockwaves Across Pharma Stocks</a></li>
</ul>

Broad U.S. Equity ETFs

ETFs

AAPL

AVGO

GOOGL

MSFT

NVDA

Fidelity NASDAQmposite Index Fund ETF-Tracking NASDAQmposite Index

ONEQ

Trump Talks Tariffs, Tech Stocks Gain As QQQ Leads The Charge

American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) raises FY2025 FFO guidance from $1.56-$1.60 to $1.58-$1.64 vs $1.58 analyst estimate..

American Healthcare REIT Raises FY2025 FFO Guidance from $1.56-$1.60 to $1.58-$1.64 vs $1.58 Est

Press Releases

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Health Care

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

General

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

Management

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Comments

Verve Therapeutics

Verve Therapeutics (VERV) Options

Verve Therapeutics (NASDAQ:VERV) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL